Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Update

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) was the recipient of a significant increase in short interest in May. As of May 29th, there was short interest totaling 625,772 shares, an increase of 613.1% from the May 14th total of 87,758 shares. Based on an average daily volume of 38,097,719 shares, the days-to-cover ratio is presently 0.0 days. Currently, 3.5% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Jupiter Neurosciences currently has an average rating of “Sell”.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Allen Capital Group LLC purchased a new stake in shares of Jupiter Neurosciences during the 4th quarter valued at $31,000. Geode Capital Management LLC grew its stake in Jupiter Neurosciences by 27.8% during the 4th quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after buying an additional 28,826 shares during the last quarter. Yorkville Advisors Global LP purchased a new position in Jupiter Neurosciences during the 4th quarter worth $135,000. Finally, Vestor Capital LLC grew its stake in Jupiter Neurosciences by 144,607.2% during the 1st quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after buying an additional 970,314 shares during the last quarter.

Jupiter Neurosciences Price Performance

Shares of JUNS traded up $0.01 during mid-day trading on Friday, reaching $0.23. 1,063,981 shares of the company’s stock traded hands, compared to its average volume of 3,558,695. The stock has a market cap of $8.49 million, a P/E ratio of -0.86 and a beta of 1.71. The stock’s 50-day moving average is $0.33 and its two-hundred day moving average is $0.63. Jupiter Neurosciences has a 12 month low of $0.17 and a 12 month high of $3.33.

Jupiter Neurosciences (NASDAQ:JUNS) last released its earnings results on Thursday, May 14th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.23 million.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.